NERV News & Events

Minerva announced a leadership transition with the appointment of Jim O'Connor as chief business officer, effective April 21, as Geoff Race, the company's president, has elected to leave the company. Race will continue to be involved with Minerva as a consultant. O'Connor most recently served at Axena Health.

Minerva announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia.